Tag: SGN-CD33A
U.S. FDA Lifts Clinical Hold Phase I Trials of Vadastuximab Talirine
The U.S. Food and Drug Administration (FDA) confirmed today that it has lifted the clinical hold on phase 1 trials of vadastuximab talirine (SGN-CD33A;...
Clinical Hold on Several Phase I Trials of Vadastuximab Talirine; Enrollment...
Earlier today Seattle Genetics, an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer, confirmed that it has...
Study Shows 76% Objective Response Rate in Newly Diagnosed Acute Myeloid...
Phase I clinical data from a study evaluating vadastuximab talirine, also known as SGN-CD33A or 33A in combination with hypomethylating agents (HMAs; azacitidine, decitabine) in...
Vadastuximab Talirine Demonstrates Encouraging Anti-leukemic Activity in Acute Myeloid Leukemia
Several presentations at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015, evaluating vadastuximab...
Phase I/II Clinical Trial of Vadastuximab Talirine Initiated in Patients with...
Earlier today Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer, confirmed that...
SGN-CD33A Demonstrates Encouraging Antitumor Activity in Acute Myeloid Leukemia
To-date, the treatment of acute myeloid leukemia or AML remains general unsatisfactory. Both the medical and scientific communities are looking for urgently needed novel...
New CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Anti-tumor Activity in...
Preclinical data from SGN-CD33A (Seattle Genetics, Inc), a novel CD33-directed antibody-drug conjugate (ADC) in development for the treatment of acute myeloid leukemia (AML) presented at...
